ClearPoint Neuro COO exercises 26,101 RSUs

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date.

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date. Each unit represented a right to receive one share of common stock.

To cover tax withholding obligations tied to this vesting, 13,281 common shares were delivered back to ClearPoint Neuro at 11.5300 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly holds 67,343 shares of common stock.

Insider Trade Summary

26,101 shares exercised/converted

Exercise 3 txns

Insider SABRA MAZIN

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	26,101	$0.00	$0.00
Exercise	Common Stock	26,101	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	13,281	$11.53	$153K

Holdings After Transaction: Restricted Stock Units — 26,101 contracts (Direct); Common Stock — 67,343 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) report for Sabra Mazin?

ClearPoint Neuro reported that COO Sabra Mazin settled 26,101 restricted stock units into common shares on their scheduled vesting date. This compensation-related event converted RSUs into stock rather than reflecting an open-market purchase.

How many ClearPoint Neuro (CLPT) shares does Sabra Mazin hold after this Form 4?

After the RSU vesting and tax withholding, Sabra Mazin directly holds 67,343 shares of ClearPoint Neuro common stock. This figure reflects the net position following the delivery of some shares back to the company for tax obligations.

Was there any open-market buying or selling by Sabra Mazin in this ClearPoint Neuro (CLPT) filing?

No open-market buying or selling occurred. The filing shows RSU settlement into 26,101 common shares and a 13,281-share tax-withholding disposition, where shares were delivered back to ClearPoint Neuro to satisfy tax obligations, not sold on the market.

What does the 13,281-share tax withholding in ClearPoint Neuro (CLPT) mean?

The 13,281 shares represent stock delivered to ClearPoint Neuro to cover tax obligations from the RSU vesting. This is a standard mechanism where part of the vested shares pays taxes instead of the insider paying cash to the tax authorities.

What type of derivative security did Sabra Mazin convert in the ClearPoint Neuro (CLPT) Form 4?

She converted restricted stock units, where each unit was a contingent right to one share of ClearPoint Neuro common stock. The Form 4 shows an exercise/conversion of 26,101 RSUs, settling them into the same number of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 02:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SABRA MAZIN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		26,101	A	(1)	80,624	D
Common Stock	03/12/2026		F		13,281(2)	D	$11.53	67,343	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/12/2026		M			26,101	(1)	(1)	Common Stock	26,101	(1)	26,101	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Mazin Sabra	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.